| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8786227 | Clinical Oncology | 2018 | 9 Pages |
Abstract
A strategy using accelerated hypofractionated 3DCRT is feasible and reasonably safe for patients with inoperable NSCLC. It is safe to deliver for centrally located tumours if DVCs are applied to the oesophagus, which is the primary dose-limiting toxicity. Further studies are required to assess the efficacy of hypofractionated regimens for centrally located tumours using an oesophageal DVC and monitoring for oesophageal toxicity.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
D.N. Cagney, P.G. Thirion, M.T. Dunne, C. Fleming, D. Fitzpatrick, C.M. O'Shea, M.A. Finn, S. O'Sullivan, C. Booth, C.D. Collins, S.J. Buckney, A. Shannon, J.G. Armstrong,